Literature DB >> 23674521

MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension.

Ryan S Friese1, Angelina E Altshuler, Kuixing Zhang, Jose Pablo Miramontes-Gonzalez, C Makena Hightower, Martin L Jirout, Rany M Salem, Jiaur R Gayen, Nitish R Mahapatra, Nilima Biswas, Mo Cale, Sucheta M Vaingankar, Hyung-Suk Kim, Maïté Courel, Laurent Taupenot, Michael G Ziegler, Nicholas J Schork, Michal Pravenec, Sushil K Mahata, Geert W Schmid-Schönbein, Daniel T O'Connor.   

Abstract

Hypertension is a common hereditary syndrome with unclear pathogenesis. Chromogranin A (Chga), which catalyzes formation and cargo storage of regulated secretory granules in neuroendocrine cells, contributes to blood pressure homeostasis centrally and peripherally. Elevated Chga occurs in spontaneously hypertensive rat (SHR) adrenal glands and plasma, but central expression is unexplored. In this report, we measured SHR and Wistar-Kyoto rat (control) Chga expression in central and peripheral nervous systems, and found Chga protein to be decreased in the SHR brainstem, yet increased in the adrenal and the plasma. By re-sequencing, we systematically identified five promoter, two coding and one 3'-untranslated region (3'-UTR) polymorphism at the SHR (versus WKY or BN) Chga locus. Using HXB/BXH recombinant inbred (RI) strain linkage and correlations, we demonstrated genetic determination of Chga expression in SHR, including a cis-quantitative trait loci (QTLs) (i.e. at the Chga locus), and such expression influenced biochemical determinants of blood pressure, including a cascade of catecholamine biosynthetic enzymes, catecholamines themselves and steroids. Luciferase reporter assays demonstrated that the 3'-UTR polymorphism (which disrupts a microRNA miR-22 motif) and promoter polymorphisms altered gene expression consistent with the decline in SHR central Chga expression. Coding region polymorphisms did not account for changes in Chga expression or function. Thus, we hypothesized that the 3'-UTR and promoter mutations lead to dysregulation (diminution) of Chga in brainstem cardiovascular control nuclei, ultimately contributing to the pathogenesis of hypertension in SHR. Accordingly, we demonstrated that in vivo administration of miR-22 antagomir to SHR causes substantial (∼18 mmHg) reductions in blood pressure, opening a novel therapeutic avenue for hypertension.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23674521      PMCID: PMC3749858          DOI: 10.1093/hmg/ddt213

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  65 in total

Review 1.  The chromogranin-secretogranin family.

Authors:  Laurent Taupenot; Kimberly L Harper; Daniel T O'Connor
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

2.  WebQTL: web-based complex trait analysis.

Authors:  Jintao Wang; Robert W Williams; Kenneth F Manly
Journal:  Neuroinformatics       Date:  2003

Review 3.  Control of translation and mRNA degradation by miRNAs and siRNAs.

Authors:  Marco Antonio Valencia-Sanchez; Jidong Liu; Gregory J Hannon; Roy Parker
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

4.  Regulation of tyrosine hydroxylase gene transcription by the cAMP-signaling pathway: involvement of multiple transcription factors.

Authors:  J Lim; C Yang; S J Hong; K S Kim
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 5.  Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system.

Authors:  Karen B Helle
Journal:  Results Probl Cell Differ       Date:  2010

6.  An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.

Authors:  Jianhua Xiong; Dianke Yu; Na Wei; Hanjiang Fu; Tianjing Cai; Yuanyu Huang; Chen Wu; Xiaofei Zheng; Quan Du; Dongxin Lin; Zicai Liang
Journal:  FEBS J       Date:  2010-02-17       Impact factor: 5.542

7.  Neuropeptide Y(1) Receptor NPY1R discovery of naturally occurring human genetic variants governing gene expression in cella as well as pleiotropic effects on autonomic activity and blood pressure in vivo.

Authors:  Lei Wang; Fangwen Rao; Kuixing Zhang; Manjula Mahata; Juan L Rodriguez-Flores; Maple M Fung; Jill Waalen; Myles G Cockburn; Bruce A Hamilton; Sushil K Mahata; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2009-09-01       Impact factor: 24.094

8.  Brain catecholamines in spontaneously hypertensive and DOCA-salt hypertensive rats.

Authors:  K Fujino
Journal:  Acta Med Okayama       Date:  1984-08       Impact factor: 0.892

9.  VISTA: computational tools for comparative genomics.

Authors:  Kelly A Frazer; Lior Pachter; Alexander Poliakov; Edward M Rubin; Inna Dubchak
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

10.  Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus.

Authors:  Laura J Lewis-Tuffin; Patrick G Quinn; Dona M Chikaraishi
Journal:  Mol Cell Neurosci       Date:  2004-03       Impact factor: 4.314

View more
  21 in total

1.  Molecular Mechanism for Hypertensive Renal Disease: Differential Regulation of Chromogranin A Expression at 3'-Untranslated Region Polymorphism C+87T by MicroRNA-107.

Authors:  Kuixing Zhang; Saiful A Mir; C Makena Hightower; Jose Pablo Miramontes-Gonzalez; Adam X Maihofer; Yuqing Chen; Sushil K Mahata; Caroline M Nievergelt; Nicholas J Schork; Barry I Freedman; Sucheta M Vaingankar; Daniel T O'Connor
Journal:  J Am Soc Nephrol       Date:  2014-11-12       Impact factor: 10.121

Review 2.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

Review 3.  The emerging role of non-coding RNA in essential hypertension and blood pressure regulation.

Authors:  F Z Marques; S A Booth; F J Charchar
Journal:  J Hum Hypertens       Date:  2014-11-13       Impact factor: 3.012

Review 4.  Noncoding RNAs in the Regulatory Network of Hypertension.

Authors:  Gengze Wu; Pedro A Jose; Chunyu Zeng
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 5.  MicroRNAs and Endothelial (Dys) Function.

Authors:  Gaetano Santulli
Journal:  J Cell Physiol       Date:  2015-12-30       Impact factor: 6.384

6.  Activation of Gαq sequesters specific transcripts into Ago2 particles.

Authors:  Lela Jackson; Madison Rennie; Alison Poussaint; Suzanne Scarlata
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

Review 7.  miR-22 in cardiac remodeling and disease.

Authors:  Zhan-Peng Huang; Da-Zhi Wang
Journal:  Trends Cardiovasc Med       Date:  2014-08-02       Impact factor: 6.677

8.  Long-term high altitude hypoxia during gestation suppresses large conductance Ca2+ -activated K+ channel function in uterine arteries: a causal role for microRNA-210.

Authors:  Xiang-Qun Hu; Chiranjib Dasgupta; Jeffery Xiao; Shumei Yang; Lubo Zhang
Journal:  J Physiol       Date:  2018-07-01       Impact factor: 5.182

9.  Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models.

Authors:  Saiful A Mir; Kuixing Zhang; Milos Milic; Yusu Gu; Timo Rieg; Michael Ziegler; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2016-01       Impact factor: 4.844

10.  Chromogranin A pathway: from pathogenic molecule to renal disease.

Authors:  Saiful A Mir; Nilima Biswas; Wai Cheung; Ji Wan; Nicholas Webster; Etienne Macedo; Daniel T O'Connor; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2020-03       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.